Alimemazine 5mg/5ml oral solution

This study introduces an oxidative derivatization procedure enabling the indirect spectrofluorometric assessment of alimemazine tartrate (ALZ). ALZ was derivatized using potassium hydrogen peroxomonosulphate (Oxone®) to yield a strongly fluorescent sulfoxide. A fast, simple, and highly sensitive fluorescence method for ALZ tartrate determination was developed based on the emission from its oxone-oxidized product in 0.05 M sulfuric acid (λex = 340 nm; λem = 380 nm). The calibration curve displayed linearity across the concentration range of 0.1–13.5 μg/mL, and the LOQ (10S) was 0.42 μg/mL, demonstrating the potential for a quantitative assay in pharmaceutical formulations, such as the film-coated tablets Theralen® 5 mg and Teraligen® 5 mg, Theralen® 4% oral drops (|((x ) ̅– μ) 100/μ| <RSD tα/√n), supporting its suitability for routine quality control and pharmaceutical analysis.

Abstract licence: CC BY 4.0

Drug-facilitated sexual assault (DFSA) may involve a diverse array of substances, including illicit drugs, prescription medications, and over-the-counter pharmaceuticals. Hair analysis has emerged as a valuable forensic tool, offering an extended window of detection spanning several months. However, interpreting drug concentrations in hair can be challenging in forensic cases, as there are still substantial disparities in drug concentration findings across studies, or even no data available in the literature. This compendium seeks to contribute to the understanding and interpretation of forensic cases involving hair analysis. This study included hair analysis results upon prosecutor request over 6 years in Grenoble Forensic Laboratory from 2019 to 2024. Segmental hair analysis was performed using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) on Sciex® 5500QT and Waters® TQ-XS mass spectrometers, following Society of Hair Testing guidelines. Screened substances included drugs of abuse, benzodiazepines, sedative medications, and gamma-hydroxybutyrate (GHB), depending on the case, following French Society of Analytical Toxicology guidelines. Hair proficiency quality testing ensured reproducible results. In this compendium, 22 authentic DFSA cases are described with hair analysis. The cohort predominantly involved female victims (95%) aged 13-47 years. Hair analysis was positive in nine cases (41%), revealing the presence of at least one psychoactive substance. Substances identified were alimemazine, alprazolam, bromazepam, cetirizine, clozapine, codeine, cyamemazine, hydroxyzine, oxazepam, zolpidem, and 3,4-methylenedioxymethamphetamine (MDMA). The chemical profile observed primarily included sedating and amnesic pharmaceuticals, but not only. This compendium adds valuable data in the literature for better hair drug concentration interpretation in forensic cases.

Abstract licence: CC BY

ObjectivesInsomnia and hypnotic consumption are major public health concerns, especially due to issues of dependence, side effects, and misuse. This study aims to describe the dispensing trends of reimbursed hypnotic tablets in France from 2012 to 2022, highlighting the potential impact of public policies designed to mainly reduce prescriptions of benzodiazepines and z-drugs.MethodsData were sourced from the Medic'AM database, managed by French National Health Insurance, which records quantities of all reimbursed medications provided by pharmacies. The study focused on 13 reimbursed hypnotics with specific French marketing authorization for insomnia, including z-drugs (zolpidem, zopiclone), antihistamines (alimemazine, doxylamine, chlorazépate+acepromazine, meprobamate+acepromazine), and benzodiazepines (lormetazepam, loprazolam, estazolam, nitrazepam, temazepam, triazolam, flunitrazepam).ResultsOver the 11-year period, alongside public health policies, a 25.30% decrease in reimbursed dispensed tablets was observed. Z-drugs saw a major 39.54% decrease, primarily due to a 69.15% drop in zolpidem prescriptions following the requirement for secure prescription pads. Antihistamines, mainly represented by alimemazine after the withdrawal and delisting of other antihistaminergic specialties, decreased by 5.48%. Benzodiazepines experienced a 16.98% reduction, mainly represented by lormetazepam and loprazolam, following the withdrawal or delisting of flunitrazepam, temazepam, and nitrazepam. Proportionally, the use of z-drugs decreased in favor of antihistamines, while benzodiazepines remained relatively stable. During the COVID-19 pandemic and its lockdowns, there was a smaller reduction in dispensed hypnotics.ConclusionsAnalyzing these trends provides insights into the potential impact of concurrent public health policies. While these trends are promising, continued efforts are necessary, emphasizing preventive and nonpharmacological measures, including improved sleep hygiene.

Abstract licence: CC BY